The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

NCT00002336 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-01-16

No results posted yet for this study

Summary

To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts \<= 100 cells/mm3.

Conditions

  • Mycobacterium Avium-intracellular Infection
  • HIV Infections

Interventions

DRUG

Clarithromycin

Sponsors & Collaborators

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-11-30
Primary Completion
1994-11-30
Completion
1994-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002336 on ClinicalTrials.gov